The aim was to investigate the potential therapeutic benefits ofGLP-1receptoragonists(GLP-1RA) on oxidative stress, mitochondrial respiration,leukocyte-endothelial interactions, inflammation and carotid intima-media thickness (CIMT) in T2D patients.
GLP-1receptoragonistsare highly effective medicines for treating diabetes and obesity, helping patients lower blood sugar, lose weight, andimproveheart and kidney health. However, their growing popularity has also revealed important challenges, including side effects, drug shortages, high costs, and misuse for cosmetic weight loss. To ensure safe and fair use, these treatments should be ...
Beyond their role in glucosemetabolism,GLP-1andits receptoragonistshave emerged as multifunctional agents with broad cardiometabolic, renal, and immunomodulatory benefits. Clinical data further reinforce these mechanistic insights.
This umbrella review synthesizes the evidence for safety and efficacyGLP-1receptoragonistson multiple outcomes including but not limited to metabolic, cardiovascular and renal outcomes.
Conclusions:GLP-1RA treatmentimprovesthe redox state and mitochondrial respiration, and reducesleukocyte-endothelial interactions, inflammation and CIMT in T2D patients, thereby potentially ...
Moving forward, it's essential to keep these visual contexts in mind when discussing Glp-1 Agonists And Improve Real Leukocyte Metabolism Yields.
In the last few years, a great interest has emerged in investigating the pleiotropic effects of Glucagon Like Peptide-1 ReceptorAgonists(GLP-1RAs). WhileGLP-1RAs ability to lower plasma glucose and to induce weight loss has allowed them to be approved for the treatment of diabetes and obesity, consistent evidences from in vitro studies and preclinical models suggested thatGLP-1RAs have ...
Effects ofGLP-1receptoragonistson mitochondrial function, inflammatory markers andleukocyte-endothelium interactions in type 2 diabetes.
